High Purity Gonador Elin Powdew CAS 33515-09-2 Raw Powder China Manufacturer

You are here: Home » PRODUCTS » Peptides (only research for lab) » High Purity Gonador Elin Powdew CAS 33515-09-2 Raw Powder China Manufacturer

High Purity Gonador Elin Powdew CAS 33515-09-2 Raw Powder China Manufacturer

Customization:	Available
Powder:	Yes
Customized:	Customized

Quantity:
Availability:





Inquire Add to Basket

Model:
CAS 33515-09-2
Brand:
Gonadorelin
Code:
CAS 33515-09-2

Gonadorelin cas 33515-09-2

Product Description

Basic Info.

Model NO.

TAPI-335

Certification

USP

Suitable for

Adult

State

Solid

Purity

>99%

Type

Pharmaceutical Intermediates

Appearance

Powder

Colour

White

Formula

C55h75n17o13

CAS No.

33515-09-2

Quality

99+

Einecs

251-553-1

Grade Standard

Pharmaceutical Grade

Shelf Life

2 Years Proper Storage

Color

White Crystalline Powder

Storage

Cool Dry Place

Model

Tapi-335

Application

API Raw Materials

CAS

33515-09-2

Test

HPLC

Assay

99%

Sample

Avaliable

1182.31

Transport Package

Standard Packaging or Customized to Your Needs

Specification

1KG 5KG 25KG 50KG

Trademark

AIKE

Origin

Zhejiang Province

HS Code

293299909

Production Capacity

5000kg/Year

Product Description

Shanghai Twochem Factory Supply High Purity Gonador Elin Powdew CAS 33515-09-2 Raw Powder

1.Free Samples.
2.MOQ:10kg.
3.More than 2000 kinds of animal drugs.
4.More than 11+ manufacturing experience.
5.Certification:MSDS,HALAL,COA,IFRA,ISO9001, ISO22000,26 Allergens, etc.
6.Lead time:about 8-12 working days.
8.Verified by Made-in-China as Golden Supplier.

Shanghai Twochem Factory Supply High Purity Gonador Elin Powdew CAS 33515-09-2 Raw Powder

What is Gonadorel CAS 33515-09-2?

Product Name	Gonadorelin
EINECS	251-553-1
Appearance	White powder
Assay	Above 99%
Test	HPLC
Certificate	ISO 9001
Storage Temperature	Keep in a cool, dry, dark location in a tightly sealed container or cylinder.

Function of Gonadorel CAS 33515-09-2

Gonadorein is a Gonadotropin-releasing hormone. Gonadorel agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and ardiovascular disease.